Patient/caregiver was educated on precautions to be exercised while taking Mitigare as follows:
- The metabolites of Mitigare along with the significant unmetabolized portion of the administered drug are excreted primarily in the urine and partially in feces. Individuals with compromised renal function cannot perform the drug clearance from the body normally, which allows the drug to stay in blood circulation for longer time, resulting in toxicity and consequent side-effects. So, Mitigare must be used with caution in individuals with compromised renal function, with possible multiple dose adjustments, periodical monitoring for renal functions, and close watch for development of any dangerous side-effects and toxicity symptoms with the medication.
- Mitigare intake, on prolonged use, can rarely also result in bone marrow suppression, resulting in reduced production of blood cells. Low red blood cell production can result in findings of anemia and individuals can present with pallor of skin and mucosa, fatigue, dizziness, shortness of breath, rapid heart rate, and other symptoms of anemia. Low white blood cell count with Mitigare intake can result in reduced immunity and increased risk for opportunistic infections. Report any findings of anemia and flare-up of opportunistic infections, following Mitigare intake, to your physician immediately, for appropriate changes in the plan of care to be considered.
